ALS amyotrophic lateral sclerosis

Health Day News reports that despite months of intense lobbying by patient advocates, federal health officials on Monday posted a largely negative review of an experimental drug for the devastating illness known as amyotrophic lateral sclerosis (ALS). In an analysis of Amylyx Pharmaceuticals' drug, known for now only as AMX3005, regulators from the U.S. Food and Drug Administration said the results were "not persuasive." They pointed to missing data, mistakes […]